Gregory Malnassy

521 total citations
14 papers, 271 citations indexed

About

Gregory Malnassy is a scholar working on Molecular Biology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Gregory Malnassy has authored 14 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Hematology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Gregory Malnassy's work include Acute Lymphoblastic Leukemia research (6 papers), Acute Myeloid Leukemia Research (5 papers) and Histone Deacetylase Inhibitors Research (2 papers). Gregory Malnassy is often cited by papers focused on Acute Lymphoblastic Leukemia research (6 papers), Acute Myeloid Leukemia Research (5 papers) and Histone Deacetylase Inhibitors Research (2 papers). Gregory Malnassy collaborates with scholars based in United States, Belgium and Germany. Gregory Malnassy's co-authors include Wendy Stock, Noreen Fulton, Houda Alachkar, Yusuke Nakamura, Richard A. Larson, Yo Matsuo, Bruce D. Cheson, Hui Liu, Claudia Linker and Karsten Spiekermann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Gregory Malnassy

14 papers receiving 269 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory Malnassy United States 9 147 86 71 37 36 14 271
Maciej Szydłowski Poland 9 151 1.0× 104 1.2× 102 1.4× 49 1.3× 27 0.8× 34 313
Ewa Jabłońska Poland 8 136 0.9× 88 1.0× 78 1.1× 47 1.3× 22 0.6× 21 275
Ari Pelcovits United States 7 121 0.8× 33 0.4× 68 1.0× 36 1.0× 110 3.1× 23 264
Cecília Correia Portugal 12 124 0.8× 58 0.7× 32 0.5× 48 1.3× 92 2.6× 25 267
Jesús María Hernández-Sánchez Spain 11 95 0.6× 42 0.5× 54 0.8× 26 0.7× 99 2.8× 21 256
Mohammad Daremipouran United States 8 176 1.2× 123 1.4× 108 1.5× 114 3.1× 18 0.5× 16 341
Randala Hamdan United States 7 255 1.7× 36 0.4× 82 1.2× 43 1.2× 14 0.4× 8 343
Olga Grzybowska‐Izydorczyk Poland 12 165 1.1× 92 1.1× 78 1.1× 53 1.4× 62 1.7× 35 356
S Jenkinson United Kingdom 5 132 0.9× 29 0.3× 53 0.7× 35 0.9× 80 2.2× 8 335
B Diouf United States 10 166 1.1× 32 0.4× 92 1.3× 39 1.1× 64 1.8× 22 371

Countries citing papers authored by Gregory Malnassy

Since Specialization
Citations

This map shows the geographic impact of Gregory Malnassy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Malnassy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Malnassy more than expected).

Fields of papers citing papers by Gregory Malnassy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Malnassy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Malnassy. The network helps show where Gregory Malnassy may publish in the future.

Co-authorship network of co-authors of Gregory Malnassy

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Malnassy. A scholar is included among the top collaborators of Gregory Malnassy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Malnassy. Gregory Malnassy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Luskin, Marlise R., Jun Yin, Gerard Lozanski, et al.. (2025). Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. 131(4). e35750–e35750. 2 indexed citations
2.
Liu, Hongtao, Yuanyuan Zha, Noura J. Choudhury, et al.. (2018). WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Experimental Hematology and Oncology. 7(1). 1–1. 18 indexed citations
3.
Malnassy, Gregory, Na Shang, Xianzhong Ding, et al.. (2018). Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatology Communications. 2(6). 732–746. 18 indexed citations
4.
Alachkar, Houda, Noreen Fulton, Gregory Malnassy, et al.. (2016). Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. The Pharmacogenomics Journal. 17(3). 274–279. 33 indexed citations
5.
Liu, Hongtao, Yuanyuan Zha, Gregory Malnassy, et al.. (2016). WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. Blood. 128(22). 3984–3984. 2 indexed citations
6.
Tamura, Kenji, Gregory Malnassy, Noreen Fulton, et al.. (2015). Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Translational Oncology. 8(5). 368–375. 19 indexed citations
7.
Alachkar, Houda, Gregory Malnassy, Jae‐Hyun Park, et al.. (2015). T-LAK cell-originated protein kinase presents a novel therapeutic target inFLT3-ITD mutated acute myeloid leukemia. Oncotarget. 6(32). 33410–33425. 21 indexed citations
8.
Odenike, Olatoyosi, Anna B. Halpern, Lucy A. Godley, et al.. (2014). A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs. 33(2). 371–379. 10 indexed citations
9.
Alachkar, Houda, Klaus H. Metzeler, Noreen Fulton, et al.. (2014). Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 5(23). 12371–12382. 58 indexed citations
10.
Díaz-Flores, Ernesto, Xavier Poiré, Gregory Malnassy, et al.. (2011). Targeting multiple signal pathways simultaneously might provide effective therapeutic strategies in acute myeloid leukemia.. Journal of Clinical Oncology. 29(15_suppl). 6546–6546. 2 indexed citations
11.
Liu, Hui, Jeffrey L. Johnson, Gregory Malnassy, et al.. (2011). Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 97(4). 579–585. 59 indexed citations
12.
13.
Odenike, Olatoyosi, Lucy A. Godley, Jozef Madžo, et al.. (2011). A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.. Journal of Clinical Oncology. 29(15_suppl). 6521–6521. 2 indexed citations
14.
Singh, Rajvir, et al.. (2010). Excessive collagen accumulation in dystrophic (mdx) respiratory musculature is independent of enhanced activation of the NF-κB pathway. Journal of the Neurological Sciences. 294(1-2). 43–50. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maciej Szydłowski Breakdown of academic impact, for papers by Ewa Jabłońska Breakdown of academic impact, for papers by Ari Pelcovits Breakdown of academic impact, for papers by Cecília Correia Breakdown of academic impact, for papers by Jesús María Hernández-Sánchez Breakdown of academic impact, for papers by Mohammad Daremipouran Breakdown of academic impact, for papers by Randala Hamdan Breakdown of academic impact, for papers by Olga Grzybowska‐Izydorczyk Breakdown of academic impact, for papers by S Jenkinson Breakdown of academic impact, for papers by B Diouf
Rankless by CCL
2026